Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for CANDLE, SAVI, Aicardi-Goutieres syndrome, and severe juvenile dermatomyositis
2015-003424-31Phase 2
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2015
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of baricitinib in Nakajo-Nishimura syndrome (NNS), STING-associated vasculopathy with onset in infancy (SAVI), juvenile dermatomyositis (JDM) and 1 more, sponsored by Eli Lilly and Company. Primary endpoint: Reduction in CANDLE diary mean daily score.
02
Drugs
baricitinib
03
Conditions
Nakajo-Nishimura syndrome (NNS)STING-associated vasculopathy with onset in infancy (SAVI)juvenile dermatomyositis (JDM)Aicardi-Goutières syndrome (AGS)
Beyond the preview
Go deeper on 2015-003424-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003424-31.